New Evidence for the Long-term Effectiveness of Interferon-beta and Copaxone

By OMS on November 19, 2018

Dr Jonny White explains the results of a 10 year prospective study into disease modifying drugs treatments for pwMS.

Vitamin K2 – The New Vitamin D In MS?

By Admin on March 20, 2018

A study appears to have found a link between multiple sclerosis and lower blood levels of VK2, a fat-soluble molecule.

The Massive Vitamin D Blunder That Has Left Millions Deficient

By Admin on March 9, 2018

New research has found that existing guidelines on recommended vitamin D intake may be dangerously low.

What Price Can We Put on Our Health?

By Admin on February 25, 2018

A new treatment called Ocrelizumab has been found to have a positive effect on RRMS, but the nature of the market could mean it stays an expensive drug.

Increasing the time between Tysabri doses reduces chance of PML

By OMSWebEditor on February 9, 2018

Tysabri is a disease-modifying drug currently given by intravenous infusion every 4 weeks and is commonly prescribed for the treatment of very active MS.

Smoking increases relapse risk in those receiving interferon treatment

By Admin on January 25, 2018

A new study has found evidence that smoking negatively impacts people with relapsing-remitting multiple sclerosis (RRMS) who are receiving interferon treatment.